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Abstract
An array of infections, including the novel coronavirus (SARS-CoV-2), trigger macrophage activation syndrome (MAS) and 
subsequently hypercytokinemia, commonly referred to as a cytokine storm (CS). It is postulated that CS is mainly responsible 
for critical COVID-19 cases, including acute respiratory distress syndrome (ARDS). Recognizing the therapeutic potential 
of Spirulina blue-green algae (Arthrospira platensis), in this in vitro stimulation study, LPS-activated macrophages and 
monocytes were treated with aqueous extracts of Spirulina, cultivated in either natural or controlled light conditions. We 
report that an extract of photosynthetically controlled Spirulina (LED Spirulina), at a concentration of 0.1 µg/mL, decreases 
macrophage and monocyte-induced TNF-α secretion levels by over 70% and 40%, respectively. We propose prompt in vivo 
studies in animal models and human subjects to determine the putative effectiveness of a natural, algae-based treatment for 
viral CS and ARDS, and explore the potential of a novel anti-TNF-α therapy.
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Introduction
The novel coronavirus disease (COVID-19) is an emerging 
contagious respiratory tract illness caused by the severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
(Hu et al. 2020). From late 2019, SARS-CoV-2 infections 
have resulted in an array of clinical responses which differ 
between individual cases, from asymptomatic conditions 
to detrimental manifestations and mortality. Whereas 
precise immune-pathological processes that COVID-19 
activates remain, as of yet, contested (Coperchini et al. 
2020), there is an ostensible agreement on the major 
mechanism by which the virus causes severe symptoms.
Epidemiological studies have indicated that exposure to 
the etiologic agent SARS-CoV-2 provokes macrophages 
and monocytes to release an excessive amount of 
different pro-inflammatory cytokines, such as tumor 
necrosis factor (TNF)-α and interleukin (IL)-6, to cause 
a hypercytokinemia, commonly referred to as a cytokine 
storm (CS) (Ishikawa 2012; Ye et al. 2020).
An influx of TNF-α, as part of the CS, destabilizes 
endothelial cell networks and induces damage of vascular 
barrier, capillary damage, diffuse alveolar damage (DAD), 
apoptotic cell death, and multi-organ failure. Furthermore, 
a recent analysis indicated higher systemic levels of IL-2, 
IL-7, IL-10, monocyte chemoattractant protein-1 (MCP-
1), macrophage inflammatory protein-1A (MIP-1A), 
and TNF-α, among critically ill COVID-19 patients 
(McGonagle et al. 2020; Ruan et al. 2020).
Specifically, excess release of TNF-α plays a critical 
role in disrupting the lung endothelial and epithelial 
barriers, which may cause acute respiratory distress 
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syndrome (ARDS) (Shimizu 2019). ARDS requires 
admission to intensive care units (ICU), where invasive 
mechanical ventilation may be administered (Mittermaier 
et al. 2020). Furthermore, it is generally accepted that 
ARDS is the main cause of death of patients with COVID 
(Mehta et al. 2020). The prevalence of COVID-19 ARDS 
incidences led to a global public health emergency, 
prompting governments to suspend social activities and 
impose unprecedented movement restriction and social 
distancing. These measures were set to maintain ICUs 
within their operational capacity limitations, a pending 
public healthcare concern (Alkuzweny et  al. 2020; 
Moghadas et al. 2020).
Considering the role of TNF-α in triggering COVID-19-
related cytokine storm syndrome (COVID-CS) and ARDS, 
it is necessary to develop new approaches for anti-TNF 
therapy. Indeed, since the outbreak of the pandemic, TNF-α 
blockers have shown promising outcomes in treating, and 
mitigating, severe illness (Robinson et al. 2020).
Herein, a novel approach is proposed for TNF-α inhibi-
tion, based on a treatment with the blue-green algae Spir-
ulina (Arthrospira platensis) extract.
The potential health benefits of Spirulina are well 
documented (Belay et al. 1993; Furmaniak et al. 2017). 
This blue-green algae contains C-phycocyanin (C-PC), a 
pigment-binding protein, which enhances antioxidation, 
anti-inflammation, and anti-tumor activities (Cian et al. 
2012; Saini and Sanyal 2015). Furthermore, Spirulina 
may be cultivated in different conditions and extracted 
using various techniques, which may affect the bioactive 
metabolite content of Spirulina (Minhas et al. 2016). Under 
certain conditions, for instance, irradiation by light-emitting 
diodes (LED) to control photosynthesis, algal bioactivity 
such as anti-inflammatory properties may be enhanced (De 
Morais et al. 2015; Ooms et al. 2016).
In this study, we exposed macrophages and monocytes 
activated by the pathogenic stimulator lipopolysaccharide 
(LPS) to different doses of Spirulina extracts, cultivated in 
either full-range solar spectrum or controlled light conditions. 
We report that an aqueous extract of a photosynthetically 
controlled Spirulina (LED Spirulina) inhibits TNF-α 
secretion by over 70% from LPS-activated macrophages and 
over 40% from LPS-activated monocyte cells.
Materials and Methods
Reagents
Cell lines for measuring anti-inflammatory activity human 
monocyte (THP-1) and murine macrophages (RAW 264.7) 
were used. All were provided by the American Type Culture 
Collection (ATCC, USA). Additionally, Rosewell Park 
Memorial Institute (RPMI) 1640, Dulbecco’s Modified Eagle 
Medium (DMEM) were purchased from ATCC. Fetal bovine 
serum (FBS), penicillin-streptomycin, sodium pyruvate, and 
glutamine were purchased from Biological Industries (Beit 
HaEmek, Israel). 2-Mercaptoethanol was purchased from BIO-
RAD and ELISA kits were purchased from PeproTech. LPS 
was purchased from Sigma-Aldrich (Sigma-Aldrich, Israel).
Culture and Extraction
Spirulina (UTEX 3086) was cultivated in Zarrouk medium 
(Rajasekaran et al. 2016). Cultivation was carried out in 
180-L flat panel airlift photobioreactors. The cultures were 
maintained under agitation induced by insufflation of filtered 
air, with flow aeration of 0.5 vvm (air volume/medium 
volume/minute).
Temperature was kept at 31 ± 2 °C and pH was maintained 
at 10.8 ± 0.2 °C. Cultures were grown under two illumination 
conditions: (A) full-range solar spectrum at irradiance of 
750 μmol/(m2s), here referred to as “Solar Spirulina”, and 
(B) red/blue/UV at irradiance of 750 μmol/(m2s) (USP # 
63/026,764), here referred to as “LED Spirulina”.
The irradiance was measured on the surface of the flask 
using a LI-250A light meter (Nebraska, USA) and a Li-Cor 
quantum sensor. Both cultures were water-extracted using 
physical freeze-thawing for cellular disruption (Chu et al. 
2010), obtaining one Solar Spirulina extract and one LED 
Spirulina extract.
Metabolomics Profile of the Full Spectrum and LED 
Spirulina Extracts
Solar and LED Spirulina extracts were dissolved in methanol 
(100 g /mL) and 5  L of the solutions were injected into a 
UHPLC connected to a photodiode array detector (Dionex 
Ultimate 3000), with a reverse-phase column (ZORBAX 
Eclipse plus C18, 3.0×100°mm, 1.8°μm).
The mobile phase consisted of (A) DDW with 0.1% 
formic acid and (B) acetonitrile containing 0.1% formic acid. 
The gradient started with 2% B then increased to 30% B in 
4 min, then increased to 40% B in 1 min and kept isocratic 
at 40% B for 3 min. Then increased to 98% B in 6 min and 
kept isocratic at 98% B for 9 min.
Phase B returned to 5% in 3 min and the column allowed 
to equilibrate at 5% B for 5 min before the next injection. The 
flow rate was 0.4 mL/min. MS/MS analysis performed with 
heated electrospray ionization (HESI-II) source connected 
to a Q Exactive™ Plus Hybrid Quadrupole-Orbitrap™ Mass 
Spectrometer Thermo Scientific™. ESI capillary voltage 
was set to 3500 V, capillary temperature to 300 °C, gas 
temperature to 350 °C, and gas flow to 35 mL/min.
The mass spectra (m/z 67–1000) acquired in negative and 
positive-ion mode with high resolution (FWHM = 70,000). 
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Data-dependent MS/MS was performed with collision 
energy of 15, 50, and 100 eV.
Measurement of the Secretions of Pro‑inflammatory 
Cytokines from RAW264.7 Macrophages
The amounts of TNF-α and IL-6 secreted from mouse 
macrophage cells were measured with TNF-α and IL-6 
ELISA kits (PeproTech) according to manufacturer 
instructions. First, RAW264.7 cells (1 × 105 cells/well) 
were inoculated into a 96-well plate and cultured for 
48 h in DMEM 5% FBS (v/v) and penicillin-streptomycin 
(100 IU/mL and 1 µg/mL) at 37 °C with 5%  CO2. Various 
concentrations of the Spirulina extracts were added 20 
min prior to LPS (100 ng/mL) stimulation for additional 
4 h of culturing. The concentrations of the cytokines were 
measured in the ELISA reader infinite M200 PRO (TECAN, 
Switzerland) at 450 nm with correction at 620 nm.
Measurement of the Secretions of Pro‑inflammatory 
Cytokines from Human THP‑1 Monocyte Cells
The amount of TNF-α secreted from human monocyte 
cells was determined with TNF-α ELISA kit (PeproTech) 
according to manufacturer instructions. THP-1 cells (1 × 105 
cells/well) were inoculated into a 96-well plate and cultured 
for 48  h in RPMI 1640 culture medium supplemented 
with 10% (v/v) heat-inactivated FBS, 1% sodium pyruvate 
(11.0  mg/mL (100  mM)), 0.05  µM 2-mercaptoethanol, 
and 1% penicillin-streptomycin (100  IU/mL and 1  µg/
mL) at 37  °C with 5%  CO2. Various concentrations of 
Spirulina extracts were added 20 min prior to LPS (100 ng/
mL) stimulation for additional 2  h of culturing. The 
concentrations of the cytokines were measured in the ELISA 
reader infinite M200 PRO (TECAN, Switzerland) at 450 nm 
with correction at 620 nm.
Data Preprocessing
Peak annotation and peak area integration performed with 
Compound Discoverer 3.1 (Thermo Xcalibur, Version 
3.1.0.305). Compound putative identification was performed 
based on MS spectral data using MzCloud database and 
HRMS and isotope profile data using ChemSpider database.
Statistical Analysis
All in vitro experimental data was obtained from three 
separate experiments performed in three replicates, 
and statistical significance was determined by one-way 
analysis of variance (ANOVA) and post hoc Tukey, using 
the Statistical Analysis System program, PRISMA 8. The 
difference between the significance levels was set to p < 0.05.
Results
Metabolomics Profile from Spirulina Extracts of Two 
Different Cultivation Conditions
The metabolomics profile from Spirulina extracts was 
determined using un-targeted LC/MS/MS. PC analysis 
of the 109 detected features (metabolites) is displayed in 
Fig. 1a. The first two principal components of the PCA 
score plot were responsible for 62.1% (43.8% for PC1 and 
18.3% for PC2) of the overall variance of the metabolomics 
profile, showing a clear separation between the Solar and 
LED Spirulina extracts. Seven compounds were significantly 
upregulated in the LED extract compared with Solar extract 
while 23 compounds downregulated (Fig. 1b). Two of the 
upregulated compounds, sorbitol and adenosine derivate, 
annotated based on MS/MS spectra using mzCloud 
database with MS/MS spectral similarity of 97% and 91%, 
respectively. These bioactive compounds significantly 
increased in the LED extract by 1.7- and 4.8-fold with P 
value of 0.01 and 7.8×10–10, respectively.
In addition, C-phycocyanin (CPC) bioactive compound was 
also significantly increased in the LED extract, by 4.7-fold.
Inhibition of Pro‑inflammatory Cytokine Secretion 
by the Extracts
Monocytes and macrophages play a pivotal role in COVID-
related CS; therefore, the inhibitory effect of the extracts related 
to CS was tested in both macrophages and monocyte cells.
Our results illustrate the effects of the two extracts (Solar 
Spirulina and LED Spirulina) on LPS-induced secretion of 
TNF-α from mouse macrophages. LED Spirulina shows 
a 70% reduction in TNF-α levels at the concentration of 
0.1 μg/mL (Fig. 2b), while no inhibitory effect was observed 
for Solar spirulina (Fig. 2a). In contrast to the inhibitory 
effect on TNF-α, LED Spirulina had no effect on the 
secretion of IL-6 at 0.1 μg/mL (Fig. 2d). Moreover, results 
indicate that at higher dose of LED Spirulina extract (10 μg/
mL), there was a minor effect on IL-6 secretion (Fig. 2d), 
while no inhibitory effect was observed on TNF-α (Fig. 2b). 
Solar Spirulina had no effect on IL-6 secretion (Fig. 2c).
Since monocytes contribute to COVID-CS (Jafarzadeh 
et al. 2020), the effect of the different Spirulina extracts was 
also assessed in human monocyte-stimulated cells (Fig. 3a, 
b). The LED-spirulina extract inhibitory effect was also 
observed in LPS-stimulated human monocyte, reducing 
TNF-α levels over 40% at the indicated concentrations.
In addition, the extracts in the absence of LPS did not 
exhibit off target effect and TNF-α or IL-6 was not detected 
in non-LPS-stimulated macrophages and monocyte cells.
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Discussion
As reported in previous studies (Feldmann et al. 2020), critically 
ill COVID-19 patients who were administered a single dose of a 
TNF- neutralizing antibody were 45% less likely to die overall, 
and more likely to be weaning from mechanical ventilation 1 
month after treatment, compared with untreated patients. This 
suggests that control of CS in its early stage through such 
means as immunomodulators and cytokine antagonists, as well 
as reduction of lung inflammatory cell infiltration, is key to 
reducing COVID-19-related mortality rates.
This study showed that LED Spirulina extract in low 
doses is able to decrease excessive release of TNF-α in LPS-
activated macrophages and LPS-activated monocyte cells 
by over 70% and 40%, respectively. If further clinical trials 
confirm these efficacy rates among human subjects, then 
LED Spirulina may act as a novel TNF-α suppressor.
The substantial inhibitory effect of LED Spirulina on 
TNF-α secretion, in contrast to an unsubstantial effect on 
IL-6 release, prompts us to assume that the LED Spirulina 
extract serves as a specific TNF-α suppressor.
It should be emphasized that LED Spirulina’s anti-TNF-α 
effect exhibited a reversed dose-response activity. This might 
suggest that very low doses of LED Spirulina extract-related 
active molecules can affect endpoints (Vandenberg 2014). A 
similar effect was shown in other plant-based whole extracts, 
exhibiting the highest activity at the lowest concentration 
(Otegbade et al. 2017).
A possible explanation for the reaction pattern observed 
in this study for TNF-α and IL-6 inhibition is that different 
bioactive molecules of LED Spirulina extract at different 
absolute quantities affect macrophages and monocyte cells 
differently, with some bioactive molecules suppressing 
TNF-α at low dosages, while others inhibit IL-6 release only 
at higher dosages.
In addition, since both Solar and LED Spirulina 
extracts include CPC, the cytokine inhibitory bioactivity 
of the LED Spirulina extract could not be explained by 
the presence of this molecule alone (Jiang et al. 2017). 
Furthermore, according to previous studies (Cherng et al. 
2007), using pure CPC on LPS-activated macrophages 
results in 40% TNF-α inhibition at 250 μg/mL. Here, we 
show inhibitory effect of 70% at 0.1 μg/mL of LED extract, 
suggesting that CPC is not the only responsible compound 
for TNF-α inhibition. As there are indications that sorbitol 
and adenosine derivate have anti-inflammatory properties 
(Mongkhon et al. 2014), the upregulation of these groups 
in LED Spirulina compared with Solar Spirulina leads us 
to suggest that the bioactivity of LED Spirulina extract 
results from a synergistic effect between several functional 




Fig. 1  Multivariate statistical analyses. The principal component 
analysis (PCA) score plots of the Solar and LED Spirulina extracts 
(a). Differential analysis that presents all the difference of the metab-
olite profile between Solar and LED Spirulina extracts (b). Dots in 
red are the upregulated compounds in the LED extract compared with 
Solar extract. Dots in green are the downregulated compounds in the 
LED extract compared with Solar extract. Squared metabolites are 
significantly increased (red) or decreased (green) at the LED extract 
compared with Solar extract with P value < 0.05 using t test statistical 
analysis
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Lastly, in order to preserve a multi-batch consistent 
bioactivity of the extract, it is essential that the algal biomass 
is cultivated under consistent and controlled conditions 
throughout the year (e.g., light composition, irradiation level, 
temperature, pH levels). Such cultivation conditions may be 
realized in a fully controlled, indoor system, uninterrupted 
by diurnal or seasonal variations.
Implications and Future Research
We suggest at least three advantages of this novel approach 
of a natural, algae-based CS shield, and note that it requires 
further research.
First, as TNF-α is a key player in many acute inflammatory 
reactions, acting as an amplifier of inflammation, algae-
based anti-TNF blockade has the potential to assist in treating 
other virus-induced CS, such as COVID-19, influenza, and 
autoimmune-related inflammatory diseases.
Second, and on condition that in  vivo experiments 
establish the effectiveness of LED Spirulina in reducing CS, 
our proposed novel treatment could be dispensed extensively 
without putting the health of patients at risk, since Spirulina 
is FDA approved as a dietary supplement, and since its 
administration is non-intrusive, and can be orally absorbed.
Third, if animal and clinical trials confirm the efficacy of 
this anti-TNF therapy at the rates reported above, and the 
substance is available to the general population, a robust 
therapeutic intervention can be expected that is independent 
of vaccines, their requisites and potential ramifications, 
including skilled healthcare workers in clinics and possible 
side effects, especially in vulnerable populations with 
chronic diseases, which could only be detected in phase 
IV clinical trial years after administration.
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Fig. 2  The secretion of TNF-α or IL-6 from LPS-induced RAW264.7 
cells after treatment with various concentrations of Solar (a, c) and 
LED (b, d) Spirulina extracts. RAW264.7 were incubated with the 
indicated doses of spirulina extract in the presence or absence of LPS 
for 4 h. TNF-α and IL-6 secretion were determined by ELISA. Val-
ues are presented as means ± SD; **p < 0.01, ****p < 0.001 and com-
pared with the LPS group
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Concomitantly, an algae-based anti-TNF therapy should 
be unaffected by variations in SARS-CoV-2 genome 
across major mutation clusters (Toyoshima et al. 2020), 
including recent mutations in SARS-CoV-2 that have 
raised concerns in regard to vaccine efficacy (Korber et al. 
2020; Kupferschmidt 2020).
An ancillary, yet substantial benefit, such as therapeutic 
intervention—should it be proven efficient in human 
subjects—will free up capacity of ICUs, enable patients 
to receive over-the-counter affordable treatment option.
Drawing on our in vitro results, we stress the need for 
prompt in vivo studies to assess the effectiveness of vari-
ous Spirulina extracts among animal models, as well as in 
clinical trials.
In addition, future research should note that the effect 
on TNF-α expression was greater than on IL-6. This 
finding suggests that the extract targets TNF-α secretion 
selectively and further validation with a more detailed 
mechanism of the anti-inflammation cascade within 
macrophages and monocyte cells should be explored.
It should likewise be noted that the extract from the 
LED-controlled cultivation process was significantly 
more effective at suppressing release of TNF-α. To 
date, no natural compound has been proven to suppress 
specifically TNF-α. Therefore, LED Spirulina could pave 
the way for novel algae-based bioactive compounds as 
anti-TNF treatment.
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